Clinical endpoints in allergen immunotherapy: State of the art 2022

被引：3
|
作者：
van Wijk, R. Gerth [1 ,4 ]
Klimek, L. [2 ]
Pfaar, O. [3 ]
机构：
[1] Erasmus MC, Dept Internal Med, Sect Allergol & Clin Immunol, Rotterdam, Netherlands
[2] Zent Rhinol & Allergol, Wiesbaden, Germany
[3] Philipps Univ Marburg, Univ Klinikum Marburg, Sekt Rhinol & Allergie, Klin Hals Nasen Ohren Heilkunde Kopf & Hals Chirur, Marburg, Germany
[4] Erasmus MC, Abt Allergol klin Immunol, Abt Innere Med, Rotterdam, Netherlands
来源：
ALLERGOLOGIE | 2023年 / 46卷 / 03期
关键词：
allergen immunotherapy; endpoints; rhinitis; asthma; real-life studies; cost-effectiveness; ASTHMA; RHINOCONJUNCTIVITIS; EFFICACY; RHINITIS; ADULTS; TRIAL;
D O I：
10.5414/ALX02334E
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
110 years after the classical study by Noon, numerous studies have confirmed the efficacy of allergen immunotherapy. A variety of clinical endpoints have been used in these trials. This review gives an overview of clinical endpoints for randomized clini-cal trials on allergen immunotherapy (AIT) in rhinitis and asthma. In addition, real-life studies have been carried out with the same kind of endpoints. In general, AIT studies are characterized by a lack of standardized and validated outcome measures. For allergic rhinoconjunctivitis, digital tools have been developed to monitor patients. Such tools are particularly useful to obtain real-world evidence for AIT. Finally, well-accepted out-come measures are available for cost-effec-tiveness studies.
引用
收藏
页码：184 / 192
页数：9
相关论文
共 50 条
  • [31] Allergen challenge tests in allergen im- munotherapy: State of the art
    Zieglmayer, P.
    Zieglmayer, R.
    Lemell, P.
    ALLERGOLOGIE, 2023, 46 (03) : 173 - 183
  • [32] Clinical contraindications to allergen immunotherapy: an EAACI position paper
    Pitsios, C.
    Demoly, P.
    Bilo, M. B.
    van Wijk, R. Gerth
    Pfaar, O.
    Sturm, G. J.
    Rodriguez del Rio, P.
    Tsoumani, M.
    Gawlik, R.
    Paraskevopoulos, G.
    Rueff, F.
    Valovirta, E.
    Papadopoulos, N. G.
    Calderon, M. A.
    ALLERGY, 2015, 70 (08) : 897 - 909
  • [33] Recombinant Allergen Immunotherapy: Clinical Evidence of Efficacy—A Review
    Melina Makatsori
    Oliver Pfaar
    Ramon Lleonart
    Moises A. Calderon
    Current Allergy and Asthma Reports, 2013, 13 : 371 - 380
  • [34] Novel adaptive design for allergen immunotherapy clinical trials
    Bonini, Sergio
    Pfaar, Oliver
    ALLERGY, 2022, 77 (07) : 1950 - 1951
  • [35] Allergen immunotherapy: From bench research to clinical application
    Bellanti, Joseph A.
    Settipane, Russell A.
    ALLERGY AND ASTHMA PROCEEDINGS, 2020, 41 (05) : 311 - 313
  • [36] Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation
    Sahiner, Umit M.
    Giovannini, Mattia
    Escribese, Maria M.
    Paoletti, Giovanni
    Heffler, Enrico
    Alvaro Lozano, Montserrat
    Barber, Domingo
    Canonica, Giorgio Walter
    Pfaar, Oliver
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (05):
  • [37] Omalizumab and allergen immunotherapy: A clinical report and review of the literature
    Carrier, C.
    Demoly, P.
    Caimmi, D.
    REVUE DES MALADIES RESPIRATOIRES, 2019, 36 (02) : 191 - 196
  • [38] Clinical bystander effect exerted by allergen immunotherapy: a hypothesis
    Ciprandi, G.
    EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 47 (02) : 62 - 63
  • [39] Adjuvants for allergen immunotherapy: experimental results and clinical perspectives
    Francis, James N.
    Durham, Stephen R.
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 4 (06) : 543 - 548
  • [40] Clinical outcomes of efficacy in food allergen immunotherapy trials
    Bartha, Irene
    Del Rio, Pablo Rodriguez
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 23 (03) : 239 - 245
12345